# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k141426   
B. Purpose for Submission: Modification of traceability to a previously cleared assay (k082340)   
C. Measurand: Folate   
D. Type of Test: Quantitative immunoassay   
E. Applicant: Roche Diagnostics, Inc.   
F. Proprietary and Established Names: Elecsys Folate III   
G. Regulatory Information:

1. Regulation section: 862.1295; Folic acid test system

2. Classification: II

3. Product code: CGN

4. Panel: 75; Clinical chemistry

# H. Intended Use:

1. Intended use(s):

Binding assay for the in vitro quantitative determination of folate in human serum. The binding assay is intended for use on Elecsys and cobas e immunoassay analyzers. Folic acid measurements are used in the diagnosis and treatment of anemias.

2. Indication(s) for use: See indications for use above

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Roche Elecsys 2010/cobas e411

# I. Device Description:

The Elecsys Folate III assay consists of the following:

Pretreatment reagent 1: Sodium 2-mercaptoethanesulfonate

Pretreatment reagent 2: Sodium hydroxide $2 5 ~ \mathrm { g / L }$

Streptavidin-coated microparticles with preservative

R1: Ruthenium labeled folate binding protein, stabilizers and preservatives

R2: Biotinylated folate, stabilizers and preservatives

Elecsys Folate III calibrators are required for the calibration of the folate III assay. The Elecsys Folate III calibrators were previously cleared in k082340 and the calibrator materials have not been changed.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Elecsys Folate III assay

2. Predicate 510(k) number(s): k082340

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Predicate (k082340)</td><td colspan="1" rowspan="1">CandidateDevice</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Intended for the in vitro quantitativedetermination of folate in human serum.Measurements obtained by thesedevices are used in the diagnosis andtreatment of anemias.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Protocol</td><td colspan="1" rowspan="1">The Elecsys Folate assay employs acompetitive test principle using naturalfolate binding protein (FBP)specific for folate. Folate in the samplecompetes with the added folate(labeled with biotin) for the bindingsites on FBP (labeled with ruthenium).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument Platform</td><td colspan="1" rowspan="1">Elecsys and cobas e immunoassayanalyzers.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">25 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Human serum.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrator</td><td colspan="1" rowspan="1">Elecsys Folate III CalSet</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Elecsys PreciControl Varia</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration Frequency</td><td colspan="1" rowspan="1">Once per reagent lot and•After 1 month when using same reagentlot•After 7 days when using same reagentkit•As required per QC findings orpertinent regulations</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Stability</td><td colspan="1" rowspan="1">Unopened:2-8°C - Up to the stated expiration dateOpened 2-8°C - 8 weeksOn Analyzers  2 weeks or 4 weekswhen stored alternatively in therefrigerator and on the analyzer, withthe total time on-board the analyzer notexceeding 10x8 hours</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Predicate (k082340)</td><td colspan="1" rowspan="1">Candidate Device</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">Standardized against theElecsys Folate II assay(k043318)</td><td colspan="1" rowspan="1">Standardized against WHOInternational Standard NIBSCcode: 03/178 material</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">1.5-20.0 ng/mL</td><td colspan="1" rowspan="1">2.0-20.0 ng/mL</td></tr><tr><td colspan="1" rowspan="1">AnalyticalSensitivity</td><td colspan="1" rowspan="1">Limit of Blank (LoB): = 0.64ng/mLLimit of Detection (LoD): = 1.5ng/mLLimit of Quantitation (LoQ): =2.0 ng/mL</td><td colspan="1" rowspan="1">Limit of Blank (LoB): = 0.64ng/mLLimit of Detection (LoD): = 1.2ng/mLLimit of Quantitation (LoQ): =2.0 ng/mL</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods

CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures

CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach

CLSI EP-09-A2-IR: Method Comparison and Bias Estimation Using Patient Samples

# L. Test Principle:

The serum sample is first incubated with the folate pretreatment reagents to release bound folate from endogenous folate binding proteins. Then, the pretreated sample is incubated with the ruthenium labeled folate binding protein and a folate complex is formed, the amount of which is dependent upon the analyte concentration in the sample. Next, streptavidin-coated microparticles and folate labeled with biotin are added and the unbound sites of the ruthenium labeled folate binding protein become occupied, with formation of a ruthenium labeled folate binding protein-folate biotin complex. The entire complex is bound to the solid phase via interaction of biotin and streptavidin. The reaction mixture is then aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are washed away and application of a voltage to the electrode induces chemiluminescent emission which is measured by a photomultiplier. Results are determined via a calibration curve.

Results are determined using a calibration curve that is generated specifically on each instrument by a 2 point calibration and a master curve (5-point-calibration) provided with the reagent bar code.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision of the Elecsys Folate III reagent was evaluated according to the CLSI EP5- A2 guideline using one cobas e411 Immunoassay analyzer and one reagent lot. The protocol consisted of testing 2 replicates of each control (PC $\varprojlim .$ PreciControl Varia) and human sera (HS) from native single donors per run, 2 runs per day in duplicate for 21 days $\scriptstyle ( \ n = 8 4 )$ ). Total and within-run precision was calculated according to EP5-A2. The results are summarized below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Within-run(Repeatability)</td><td rowspan=1 colspan=2>Total (IntermediatePrecision)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=1>SD(ng/mL)</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD(ng/mL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Humanserum 1</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>10.8</td></tr><tr><td rowspan=1 colspan=1>Humanserum 2</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>8.1</td></tr><tr><td rowspan=1 colspan=1>Humanserum 3</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>Humanserum 4</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>Humanserum 5</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>PC Varia 1</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>9.5</td></tr><tr><td rowspan=1 colspan=1>PC Varia 2</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>4.9</td></tr></table>

# b. Linearity/assay reportable range:

The linearity of the Elecsys Folate III was evaluated on the cobas e411 Immunoassay Analyzer using CLSI EP6-A as a guideline. Serum linearity was determined by diluting a high analyte serum sample with low analyte serum sample pool. A total of 14 different concentrations of folate ranging from $1 . 8 ~ \mathrm { n g / m L }$ to $2 1 . 7 \mathrm { n g / m L }$ were tested in triplicate within a single run. The linear equation generated is $\mathrm { y } { = } 1 . 0 9 6 9 \mathrm { x } \ \cdot$ - 1.2552 with a regression coefficient $( \mathbb { R } ^ { 2 } )$ of 0.997. A polynomial regression analysis was conducted and the $3 ^ { \mathrm { r d } }$ order was found to be significant. The deviation of the ${ \mathfrak { z } } ^ { \mathrm { r d } }$ order regression was compared against to the first order regression (see table below).

<table><tr><td rowspan=1 colspan=1>SampleNumber</td><td rowspan=1 colspan=1>Linear regression(First order) inng/mL</td><td rowspan=1 colspan=1>Predicted thirdorder in ng/mL</td><td rowspan=1 colspan=1>Absolutedifference inng/mL</td><td rowspan=1 colspan=1>Relativedifference in%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.7248</td><td rowspan=1 colspan=1>0.9813</td><td rowspan=1 colspan=1>0.2565</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.3852</td><td rowspan=1 colspan=1>1.4759</td><td rowspan=1 colspan=1>0.0908</td><td rowspan=1 colspan=1>6.5515</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.7059</td><td rowspan=1 colspan=1>2.5535</td><td rowspan=1 colspan=1>-0.1524</td><td rowspan=1 colspan=1>-5.6329</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4.0255</td><td rowspan=1 colspan=1>3.734</td><td rowspan=1 colspan=1>-0.2915</td><td rowspan=1 colspan=1>-7.2425</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6.667</td><td rowspan=1 colspan=1>6.3524</td><td rowspan=1 colspan=1>-0.3245</td><td rowspan=1 colspan=1>-4.8674</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>9.3073</td><td rowspan=1 colspan=1>9.1666</td><td rowspan=1 colspan=1>-0.1406</td><td rowspan=1 colspan=1>-1.5111</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>11.9476</td><td rowspan=1 colspan=1>12.0751</td><td rowspan=1 colspan=1>0.1275</td><td rowspan=1 colspan=1>1.067</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>14.588</td><td rowspan=1 colspan=1>14.9353</td><td rowspan=1 colspan=1>0.3474</td><td rowspan=1 colspan=1>2.3812</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>15.9087</td><td rowspan=1 colspan=1>16.3065</td><td rowspan=1 colspan=1>0.3978</td><td rowspan=1 colspan=1>2.5007</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>18.549</td><td rowspan=1 colspan=1>18.8459</td><td rowspan=1 colspan=1>0.2969</td><td rowspan=1 colspan=1>1.6005</td></tr></table>

The results of the linearity study support the sponsor’s claim that the assay is linear from 2 to $2 0 ~ \mathrm { n g / m L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Elecsys Folate III CalSet, CalCheck and the PreciControl Varia products were previously cleared in k082340 and k111506 (PreciControl Varia).

# d. Detection limit:

The Limit of Blank (LOB), Limit of Detection (LOD) and Limit of Quantitation (LOQ) were determined in accordance with CLSI EP17-A guideline. A zero level (blank) sample buffered in human serum albumin was used for the LOB studies. The LOB was determined as the 95th percentile of measurements of blank samples. The Sponsor claims a LoB value of $0 . 6 0 \mathrm { n g / m L }$ . For LOD determination, five low-level serum samples (native as well as diluted with Elecsys Diluent Universal) were used. The LOD was calculated as $\mathrm { L O D } = \mathrm { L O B } + 1 . 6 5 3 \mathrm { ~ x ~ S D }$ total. The Sponsor claims a LoD value of $1 . 2 \ : \mathrm { n g / m L }$ . For LOQ determination, a low level sample set of 10 human serum samples with folate concentrations ranging from 0.9 to $3 . 5 ~ \mathrm { { n g / m L } }$ were evaluated using 12 replicates/sample/lot across 3 reagent lots to calculate the concentration which corresponds to an inter-assay coefficient of variation (CV) of $20 \%$ . The Sponsor claims a LOQ value of $2 . 0 \mathrm { n g / m L }$ . This assay has a measuring range of $2 - 2 0 \mathrm { n g / m L }$ for serum folate.

# e. Analytical specificity:

The cross-reactivity of the Elecsys Folate III assay was determined using 3 serum samples, with approximate folate concentrations of 4, 9 and $1 8 ~ \mathrm { n g / m L }$ folate, from single native donors spiked with amethopterin, aminopterin and folonic acid. The spiked and non-spiked samples were tested in duplicate on the cobas e 411 Immunoassay analyzer.

Cross-reactivity studies were performed and a summary of the results are listed below:

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>MaximumConcentrationTested (ng/mL)</td><td rowspan=1 colspan=1>Highest % cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>Amethopterin</td><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>Aminopterin</td><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>Folonic Acid</td><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>0.7</td></tr></table>

The labeling states the following regarding cross-reactive compounds: It is contraindicated to measure samples of patients receiving therapy with certain pharmaceuticals, e.g. methotrexate or leucovorin, because of the cross‑reactivity of folate binding protein with these compounds.

The effects of endogenous interference by Biotin, Lipemia, Bilirubin, Rheumatoid Factor, Human IgG, Human IgA and Human $\mathrm { I g M }$ on the quantitation of Folate by the Elecsys Folate III assay were determined on the cobas $\mathtt { e 4 1 1 }$ Immunoassay Analyzer. One aliquot of human serum samples containing low, mid and high folate concentrations (approximately 3, 9 and $1 9 \mathrm { n g / m L }$ ) was spiked with interfering samples. The second aliquot of serum samples was spiked with the same volume of sample diluent. The interferent spiked sample was then diluted into the unspiked aliquot in $10 \%$ increments. Percent recovery was calculated by comparing the measured folate concentration to the expected folate initial concentration. No significant interference was defined as $\leq 0 . 4 ~ \mathrm { n g / m L }$ for samples $< 4 . 0 \ \mathrm { n g / m L }$ and $\leq$ $10 \%$ for samples ${ \mathrm { > } } 4 ~ \mathrm { n g / m L }$ . The following results were obtained:

<table><tr><td rowspan=1 colspan=1>Endogenous Substance</td><td rowspan=1 colspan=1>Concentration Showing No SignificantInterference</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>21 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Intralipid (Lipemia)</td><td rowspan=1 colspan=1>1500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>29 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatic Factor</td><td rowspan=1 colspan=1>1000 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Human IgG</td><td rowspan=1 colspan=1>16 g/L</td></tr><tr><td rowspan=1 colspan=1>HumanIgM</td><td rowspan=1 colspan=1>10 g/L</td></tr><tr><td rowspan=1 colspan=1>Human IgA</td><td rowspan=1 colspan=1>4 g/L</td></tr></table>

The labeling states the following regarding hemoglobin interference: Hemolysis may significantly increase folate values due to high concentrations of folate in red blood cells. Therefore, hemolyzed samples are not suitable for use in this assay.

Sixteen commonly used pharmaceuticals were examined for potential effect on folate determination by the Folate III assay. Each drug, including erythropoietin, was spiked into 3 different human folate serum samples (approximate folate concentrations of 4, 11 and $1 8 ~ \mathrm { { n g / m L } }$ ) and were tested in 13 replicates using the cobas e411 Immunoassay

Analyzer. The mean value was compared to the reference value (folate sample with no drug added) and the deviation from the reference value was calculated. No significant interference was defined interference as $\leq 0 . 4 ~ \mathrm { n g / m L }$ for samples ${ < } 4 . 0$ $\mathrm { n g / m L }$ and $\leq 1 0 \%$ for samples ${ \mathrm { > } } 4 ~ \mathrm { n g / m L }$ . The results showed no significant interference at the concentrations below:

<table><tr><td rowspan=1 colspan=1>Drug Substance</td><td rowspan=1 colspan=1>Concentration Showing No SignificantInterference</td></tr><tr><td rowspan=1 colspan=1>Acetylcystein</td><td rowspan=1 colspan=1>566 mg/L</td></tr><tr><td rowspan=1 colspan=1>Ampicillin-Na</td><td rowspan=1 colspan=1>1000 mg/L</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>300 mg/L</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine</td><td rowspan=1 colspan=1>5 mg/L</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>660 mg/L</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>5000 U</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>20 mg/L</td></tr><tr><td rowspan=1 colspan=1>Methyldopa + 1.5</td><td rowspan=1 colspan=1>20 mg/L</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>200 mg/L</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>400 mg/L</td></tr><tr><td rowspan=1 colspan=1>Doxycyclin</td><td rowspan=1 colspan=1>50 mg/L</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>1000 mg/L</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>60 mg/L</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200 mg/L</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500 mg/L</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>100 mg/L</td></tr><tr><td rowspan=1 colspan=1>Erythropoietin</td><td rowspan=1 colspan=1>2000 U/mL</td></tr></table>

f. Assay cut-off:

Not applicable.

2. Comparison studies:

# a. Method comparison with predicate device:

A method comparison study was performed with the Abbott Architect Folate assay (k092740), which is also traceable to WHO 03/178 reference material. One hundred and six native serum samples with folate values ranging from 2.08 to $1 9 . 6 \mathrm { n g / m L }$ were tested on the cobas e 411. Results are shown below (Deming Regression):

$$
\mathrm { y } = 0 . 9 7 6 \mathrm { x } + 0 . 0 4 1 ; \mathrm { r } = 0 . 9 8 4
$$

b. Matrix comparison: Not applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

A reference range study was performed to update the reference range values for the current assay after standardization to the WHO International Standard NIBSC 03/178. Clinical samples previously collected to establish the reference range for the predicate device were used to establish the reference interval. The samples tested include 214 serum samples from apparently healthy adults, fasting males $\scriptstyle ( \mathrm { N = 1 } 1 0$ ) and fasting nonpregnant females $\scriptstyle ( \mathrm { N } = 1 0 4 )$ ) between 21-59 years old. All samples were measured on the cobas e 411 over 3 runs for 2 days. The reference interval for the current assay is $4 . 8 -$ $2 4 . 2 \mathrm { n g / m L }$ (2.5th - 97.5th percentile), with a median value of $1 1 . 8 ~ \mathrm { n g / m L }$ .

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.